Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BioTools Bridges the Empirical: Computational Chemistry Chasm with ComputeVOA

Published: Thursday, June 06, 2013
Last Updated: Wednesday, June 05, 2013
Bookmark and Share
ComputeVOA uses Vibrational Circular Dichroism to determine the three-dimensional structure of chiral molecules.

Chiral molecules, those “left/right” mirror image marvels of nature, determine much of our biology and, as a result, are of prime interest to biologists, organic chemists, and especially, the pharmaceutical industry.

But which of the left/right stereoisomers has the optimum chemical activity? BioTools (Jupiter, FL) answers that question.

They capitalized on the recent American Chemical Society meeting (April 7-10, New Orleans, LA) to launch ComputeVOA, an innovative, easy-to-use software package which uses Vibrational Circular Dichroism (VCD) to determine the three-dimensional structure of chiral molecules and their predicted spectra.

“Chirality and the resulting molecular behavior is a hot topic for many students and practicing organic and pharmaceutical chemists,” cited BioTools’ President, Dr. Rina Dukor.

Dr. Dukor continued, “They all have chemical drawing programs. ComputeVOA empowers them to take the next steps: select an actual 3D structure, determine the energy optimizations, identify the potential stereo isomer structure (called a ‘conformer’), then calculate its IR and VCD spectra.”

Once plotted, the calculated spectra can then be compared to an empirically measured spectra, providing an unambiguous determination of the molecule’s absolute stereo-specific structure, saving years of experimental time and expense.

Pharma has been an early VCD adopter, propelled by the need to define three-dimensional structure and the resulting biological activity of drug candidates as early as possible in the product development process.

According to a GIA report on the Chiral Technology Market (April 2012), by 2020, 95% of all pharmaceutical drugs will be chiral. The driving factor: greater therapeutic effectiveness of single-enantiomer compounds.

In the most successful companies, analytical chemists have partnered with senior computational chemists to achieve these calculations, often using three or four programs, or even writing their own, to model molecules.

“The new software changes all of that,” explains Dr. Dukor. “With the exception of very complex molecules, ComputeVOA provides one, facile platform which opens access to chiral characterization across the analytical spectrum, from students and entry level scientists to technicians and general analytical chemist.”

ComputeVOA orchestrates a complex molecular dance. Data enters the stream through a molecule builder/structure importer then moves into a robust molecular mechanics conformational search algorithm.

The results then pass through a transparent handshake to Gaussian 09 (Gaussian, Inc. Pittsburgh, PA) where quantum mechanics determines the molecule’s structure and properties.

It then returns seamlessly to ComputeVOA for a Boltzmann-averaging of conformers and plotting of the IR and VCD spectra.

The final output: The specific stereo isomers’ 3D structure and accompanying InfraRed and Vibrational Circular Dichroism spectra.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Combining Chemotherapy With Immune-Blocking Drug Could Stop Cancer Growing Back
Giving patients a drug that blocks part of the immune system from going into overdrive might help prevent cancer coming back in some people.
Researchers Pioneer Use of Capsules to Save Materials
Wax capsule delivery systems can simplify a wide range of chemistry transformations.
Photoredox Catalyst Unlocks New Pathways for Nickel Chemistry
Using a light-activated catalyst, researchers have unlocked a new pathway in nickel chemistry to construct carbon-oxygen (C-O) bonds that would be highly valuable to pharmaceutical and agrochemical industries.
Scientists Determine How Antibiotic Gains Cancer-Killing Sulfur Atoms
In a discovery with implications for future drug design scientists have shown an unprecedented mechanism for how a natural antibiotic with antitumor properties incorporates sulfur into its molecular structure, an essential ingredient of its antitumor activity.
Familiar Drugs May Block Ebola Virus Infection
A well-known class of molecules, many of which are already in use therapeutically, may be able to block the Ebola virus’s entry into cells and halt the disease in its tracks, according to researchers at the University of Illinois at Chicago.
New Extra ‘Sticky’ Microgel Could Revolutionise Bladder Cancer Treatment
Researchers have designed a new super-efficient way of delivering an anti-cancer drug which could extend and improve the quality of life for bladder cancer patients - and perhaps save lives.
Common Class of ‘Channel Blocking’ Drugs May Find a Role in Cancer Therapy
Discoveries in fruit flies prompt unusual treatment of patient with metastatic disease.
Common Medications Could Delay Brain Injury Recovery
Drugs used to treat common complaints could delay the recovery of brain injury patients according to research by University of East Anglia (UEA) and University of Aberdeen scientists, published today in Brain Injury.
Scientists Make Strides in Therapy Preventing Addiction Relapse
Single Injection of Drug Candidate Prevents Meth Relapse in Animal Models.
New Clot-Busting Treatments Target Number One Killer
Australian researchers funded by the National Heart Foundation are a step closer to a safer and more effective way to treat heart attack and stroke via nanotechnology.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!